BioCryst Pharmaceuticals
Quarterly Financials
| Values in thousands | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
Revenue | $156,413 | $406,555 | $159,395 | $163,353 |
Gross Profit | -546,725 | 396,639 | 156,873 | 160,555 |
EBITDA | -701,598 | 266,196 | 32,126 | 28,397 |
EBIT | -702,659 | 262,152 | 31,791 | 28,068 |
Net Income | -721,812 | 245,845 | 12,899 | 5,085 |
Net Change In Cash | 156,413 | 406,555 | 159,395 | 163,353 |
Free Cash Flow | -62,539 | 275,234 | 39,767 | 41,123 |
Cash | 172,445 | 89,736 | 84,078 | 88,033 |
Basic Shares | 242,258 | 219,263 | 219,885 | 219,886 |
Annual Financials
| Values in thousands | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
Revenue | $874,837 | $450,712 | $331,412 | $270,827 |
Gross Profit | 855,762 | 438,227 | 326,751 | 264,233 |
EBITDA | 347,652 | 12,808 | -116,335 | -143,854 |
EBIT | 346,263 | 11,562 | -117,990 | -145,291 |
Net Income | 263,861 | -88,881 | -226,539 | -247,116 |
Net Change In Cash | 874,837 | 450,712 | 331,412 | 270,827 |
Free Cash Flow | 327,412 | -53,144 | -97,309 | -163,201 |
Cash | 89,736 | 104,923 | 110,643 | 304,767 |
Basic Shares | 218,581 | 206,696 | 192,198 | 185,908 |
Earnings Calls
| Quarter | EPS |
|---|---|
2026-03-31 | $0.14 |
2025-12-31 | $1.12 |
2025-09-30 | $0.16 |
2025-06-30 | $0.04 |